Abstract
Background: Ovarian cancer is the most malignant tumor in gynecological tumors, with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs.
Methods: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer, drug resistance, and LncRNA retrieved from the LncRNA Disease database.
Results/Conclusion: With the development of the study on drug resistance of ovarian cancer, the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance.
Keywords: Ovarian cancer, chemoresistance, long non-coding RNA, LncRNA, drug resistance, gynecological tumors.
Current Pharmaceutical Design
Title:The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer
Volume: 25 Issue: 8
Author(s): Jiayuan Qu, Mohammad Amjad Kamal and Chengfu Yuan*
Affiliation:
- Department of Biochemistry, China Three Gorges University, Yichang 443002,China
Keywords: Ovarian cancer, chemoresistance, long non-coding RNA, LncRNA, drug resistance, gynecological tumors.
Abstract:
Background: Ovarian cancer is the most malignant tumor in gynecological tumors, with low five-year survival rate. The main reasons are diagnosis at advanced stages (the early symptoms are uncharacteristic, and most are diagnosedlate.), relapse, and resistance to existing chemotherapy drugs.
Methods: Search strategy was performed in the following steps. Firstly, LncRNA related to ovarian cancer was retrieved by using the LncRNA Disease database, and articles were searched by searching keywords: ovarian cancer, drug resistance, and LncRNA retrieved from the LncRNA Disease database.
Results/Conclusion: With the development of the study on drug resistance of ovarian cancer, the role of LncRNAs as sensitive biomarker and therapeutic target has emerged, providing a direction for precision medicine of ovarian cancer resistance.
Export Options
About this article
Cite this article as:
Qu Jiayuan, Kamal Amjad Mohammad and Yuan Chengfu*, The Regulatory Roles of Long Non-Coding RNA in the Chemoresistance Process of Ovarian cancer , Current Pharmaceutical Design 2019; 25 (8) . https://dx.doi.org/10.2174/1381612825666190404122154
DOI https://dx.doi.org/10.2174/1381612825666190404122154 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Natural Membrane Vesicle Exosome-based Sinomenine Delivery Platform for Hepatic Carcinoma Therapy
Current Topics in Medicinal Chemistry Role of Microtubules Network in CYP Genes Expression
Current Drug Metabolism Doing the Puzzle of Steroid Hormone Action: Biological Functions, Physiological and Clinical Significance of Plasma Membrane-Residing Glucocorticoid Recognizing Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) p53 Activation by Blocking Snail : A Novel Pharmacological Strategy for Cancer
Current Pharmaceutical Design Lessons from Nature: Sources and Strategies for Developing AMPK Activators for Cancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment
Current Drug Targets Colon Targeted Liposomal Systems (CTLS): Theranostic Potential
Current Molecular Medicine Subject Index To Volume 13
Protein & Peptide Letters Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer
Current Cancer Drug Targets Proteinases as Biomarkers in Breast Cancer Prognosis and Diagnosis
Mini-Reviews in Medicinal Chemistry The Contribution of Extracellular Nef to HIV-Induced Pathogenesis
Current Drug Targets Reproductive Toxicity of T Cells in Early Life: Abnormal Immune Development and Postnatal Diseases
Current Drug Targets Current Concepts on Cardiovascular Stent Devices
Mini-Reviews in Medicinal Chemistry Immunology of Gynecologic Neoplasms: Analysis of the Prognostic Significance of the Immune Status
Current Cancer Drug Targets Therapeutic Antibodies for Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Intracellular Calcium Homeostasis and Kidney Disease
Current Medicinal Chemistry Anti-VEGF Anticancer Drugs: Mind the Hypertension
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Novel Therapeutic Approaches in Pancreatic Cancer Based on Genomic Alterations
Current Pharmaceutical Design Synthesis and Anticancer Activity of Some 2-[3/4-(2-Substituted Phenyl-2- oxoethoxy)benzylidene]-6-substituted-2,3-dihydro-1H-inden-1-one Derivatives
Letters in Drug Design & Discovery Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Therapeutics: Rationales, Controversies, Clinical Experience
Current Drug Targets